Phase 3 evidence, its limits and the illicit market

Retatrutide Phase 3 Results: How Much Weight Was Lost—and Why It Is Still Not Available

Retatrutide has reached phase 3 with important results in obesity, with and without type 2 diabetes. That strengthens the evidence for the studied molecule—but it does not mean approval, availability or authenticity for vials sold online as Reta or GLP-3.

Written by Eduardo FrançoisCRN-1 28284Updated October 2026

What TRIUMPH-1 found

The phase 3 randomised trial followed 2,339 adults with obesity and without diabetes for 80 weeks. In the primary analysis, average weight loss was 17.6% with 4 mg, 23.7% with 9 mg and 25.0% with 12 mg, compared with 3.9% with placebo. These are group averages under a clinical protocol, not a promise that every person will lose one quarter of their weight.

Knee pain and sleep apnoea were also assessed

The programme included participants with knee osteoarthritis and obstructive sleep apnoea. Prespecified analyses found improvements in knee pain and the apnoea–hypopnoea index. These findings are clinically relevant, but they do not establish cardiovascular benefit or show that every improvement occurred independently of weight loss.

What changes when type 2 diabetes is present

TRIUMPH-2, published in The Lancet, included 1,152 adults with overweight or obesity and type 2 diabetes. In the efficacy estimand, average weight loss at 80 weeks was 12.7% with 4 mg, 19.1% with 9 mg and 20.8% with 12 mg, compared with 4.0% with placebo. Populations, estimands and background treatment differed, so the percentages should not be combined as though they came from one experiment.

Strong efficacy does not end the safety assessment

Gastrointestinal events including diarrhoea, nausea, constipation and vomiting were the most common. Treatment discontinuations due to adverse events and other signals also require attention. Phase 3 trials broaden the safety database, but rare events, longer use and performance outside research settings still require surveillance.

It is still neither approved nor available

Retatrutide remains investigational. Lilly has stated that it plans a US regulatory submission in 2027, but a submission is not an approval, a launch date or Brazilian authorisation. Authentic retatrutide therefore remains within regulated clinical development.

Reta and GLP-3 do not prove identity

GLP-3 is an internet nickname, not a recognised scientific drug class. Labels such as Reta, compounded peptide or research use only do not show that a vial contains retatrutide. Outside a regulated trial, origin, concentration, purity, sterility and storage cannot be assumed.

The warning that made the risk concrete

In September 2026, Australian authorities investigated a product sold as retatrutide after a user developed uncontrolled vomiting and a serious oesophageal injury. Reported testing found semaglutide rather than retatrutide, at a concentration far above that seen in approved products. This was not an adverse effect of authentic retatrutide; it showed the danger of not knowing what a vial contains.

Clinical results do not validate copies

Trial participants received a controlled product, dose escalation, clinical screening and monitoring. None of this can be assumed for a substance bought through social media, a gym, a clinic or an informal vendor. Alongside the wrong active ingredient or dose, an illicit injectable may be contaminated, non-sterile, degraded or incorrectly stored.

How to interpret the situation today

The balanced conclusion has two parts: retatrutide produced substantial efficacy in the studied populations, and it remains investigational; any direct public sale therefore sits outside regular clinical access. Persistent vomiting, severe pain, dehydration or an allergic reaction after an unapproved product requires medical assessment.

Personalized care

A plan should fit the person, not the trend.

Book a consultation

Scientific references

This page is educational and does not replace individual medical or nutrition assessment.